Review article
Pharmacokinetics in older persons

https://doi.org/10.1016/j.amjopharm.2004.12.005Get rights and content

Abstract

Background:

Physiologic changes and disease-related alterations in organ function occur with aging. These changes can affect drug pharmacokinetics in older persons.

Objective:

This article reviews age-related changes in pharmacokinetics and their clinical relevance.

Methods:

A PubMed search was conducted using the terms elderly and pharmacokinetics. Other reviews were also included for literature searching. The review includes literature in particular from 1990 through April 2004. Some particles from before 1990 were included to help illustrate principles of age-related pharmacokinetics.

Results:

There are minor changes in drug absorption with aging. The effect of aging on small-bowel transporter systems is not yet fully established. Bioavailability of highly extracted drugs often is increased with age. Transdermal absorption may be delayed, especially in the case of water-soluble compounds. Fat-soluble drugs may distribute more widely and water-soluble drugs less extensively in older persons. Hepatic drug metabolism shows wide interindividual variation, and in many cases, there is an age-related decline in elimination of metabolized drugs, particularly eliminated by the cytochrome enzyme system. Any decrement in cytochrome enzyme metabolism appears nonselective. Synthetic conjugation metabolism is less affected by age. Pseudocapillarization of the sinusoidal endothelium in the liver, restricting oxygen diffusion, and the decline in liver size and liver blood flow may influence age-related changes in rate of hepatic metabolism. Frailty, physiological stress, and illness are important predictors of drug metabolism in older individuals. Inhibition of drug metabolism is not altered with aging, but induction is reduced in a minority of studies. Renal drug elimination typically declines with age, commensurate with the fall in creatinine clearance. Renal tubular organic acid transport may decline with age, while the function of the organic base transporter is preserved but may be less responsive to stimulation.

Conclusion:

Changes in pharmacokinetics occur due to age-related physiologic perturbations. These changes contribute to altered dose requirements in older persons, particularly in the case of drugs eliminated by the kidney. Interindividual variation, disease, frailty, and stress may overshadow age-related changes.

References (229)

  • CoggerVC et al.

    Hepatic sinusoidal pseudocapillarization with aging in the non-human primate

    Exp Gerontol

    (2003)
  • WoodhouseKW

    Pharmacokinetics of drugs in the elderly

    J R Soc Med

    (1994)
  • AbernethyDR

    Altered pharmacodynamics of cardiovascular drugs and their relation to altered pharmacokinetics in elderly patients

    Clin Geriatr Med

    (2000)
  • CloydJC et al.

    Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics

    Arch Fam Med

    (1994)
  • DurnasC et al.

    Hepatic drug metabolism and aging

    Clin Pharmacokinet

    (1990)
  • GreenblattDJ et al.

    Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I)

    Clin Pharmacokinet

    (1991)
  • GreenblattDJ et al.

    Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II)

    Clin Pharmacokinet

    (1991)
  • MontamatSC et al.

    Management of drug therapy in the elderly

    N Engl J Med.

    (1989)
  • ParkerBM et al.

    Pharmacokinetic optimisation of drug therapy in elderly patients

    Drugs Aging

    (1995)
  • von MoltkeLL et al.

    Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications

    Clin Pharmacokinet.

    (1993)
  • WoodhouseK

    Drugs and the liver. Part III: Ageing of the liver and the metabolism of drugs

    Biopharm Drug Dispos.

    (1992)
  • KinironsMT et al.

    Drug metabolism and ageing

    Br J Clin Pharmacol

    (2004)
  • KlotzU

    Effect of age on pharmacokinetics and pharmacodynamics in man

    Int J Clin Pharmacol Ther

    (1998)
  • MuhlbergW et al.

    Age-dependent changes of the kidneys: Pharmacological implications

    Gerontology

    (1999)
  • SchumuckerDL

    Aging and the liver: An update

    J Gerontol A Biol Sci Med Sci

    (1998)
  • VestalRE

    Aging and pharmacology

    Cancer

    (1997)
  • OberbauerR et al.

    Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly

    Clin Pharmacol Ther

    (1995)
  • SchwinghammerTL et al.

    Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects

    J Clin Pharmacol.

    (1990)
  • LjungbergB et al.

    Pharmacokinetics of ciprofloxacin in the elderly: Increased oral bioavailability and reduced renal clearance

    Eur J Clin Microbiol Infect Dis

    (1989)
  • RochdiM et al.

    Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects

    Eur J Clin Pharmacol.

    (1994)
  • GathJ et al.

    Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients

    J Clin Pharmacol

    (1995)
  • OberbauerR et al.

    Pharmacokinetics of indomethacin in the elderly

    Clin Pharmacokinet

    (1993)
  • GouldSE et al.

    Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?

    Cardiovasc Drugs Ther

    (1990)
  • PritchardJF et al.

    Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteers

    Clin Pharmacol Ther

    (1992)
  • WynneHA et al.

    The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide

    Age Ageing

    (1993)
  • BaillieSP et al.

    Age and the pharmacokinetics of morphine

    Age Ageing

    (1989)
  • ZhaoJJ et al.

    Pharmacokinetics and bioavailabity of montelukast sodium (MK-0476) in healthy young and elderly volunteers

    Biopharm Drug Dispos.

    (1997)
  • JaillonP et al.

    Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients

    Clin Pharmacol Ther

    (1989)
  • PerretC et al.

    Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers

    Chemotherapy

    (2002)
  • GainsboroughN et al.

    The association of age with gastric emptying

    Age Ageing

    (1993)
  • CusackB et al.

    Protein binding and disposition of lignocaine in the elderly

    Eur J Clin Pharmacol

    (1985)
  • StorsteinL et al.

    Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients

    Acta Med Scand Suppl.

    (1984)
  • KellyJG et al.

    Bioavailability of labetalol increases with age

    Br J Clin Pharmacol

    (1982)
  • von RichterO et al.

    Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens

    Clin Pharmacol Ther

    (2004)
  • GrevelJ et al.

    Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients

    J Clin Pharmacol

    (1989)
  • LownKS et al.

    Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression

    J Clin Invest

    (1997)
  • DresserGK et al.

    Grapefruit juice—felodipine interaction in the elderly

    Clin Pharmacol Ther

    (2000)
  • HammanMA et al.

    The effect of rifampin administration on the disposition of fexofenadine

    Clin Pharmacol Ther

    (2001)
  • DresserGK et al.

    Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine

    Clin Pharmacol Ther

    (2002)
  • DillWA et al.

    Studies on 5, 5′-diphenylhydantoin (dilantin) in animals and man

    J Pharmacol Exp Ther

    (1956)
  • Cited by (0)

    View full text